DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Gemtuzumab ozogamicin
Gemtuzumab ozogamicin
Antibody–Drug Conjugates
Whither Radioimmunotherapy: to Be Or Not to Be? Damian J
Monoclonal Antibodies
F. Gherlinzoni CD33: Gemtuzumab Ozogamicin
Antibody–Drug Conjugates: the Last Decade
Antibody-Drug Conjugates of Calicheamicin Derivative: Gemtuzumab Ozogamicin and Inotuzumab Ozogamicin
Systemic Therapy Update
The Role of Monoclonal Antibodies in the Management of Leukemia
Antibody Drug Conjugates for Cancer Treatment
Dual Kinase Targeting in Leukemia
Antibody–Drug Conjugates for Cancer Therapy
View of This Manuscript
Mylotarg® (Gemtuzumab Ozogamicin)
Systemic Therapy Update
The Safety of Antibody Drug Conjugates: a Literature Review
Antibody Drug Conjugates: Future Directions in Clinical and Translational Strategies to 2 Improve the Therapeutic Index
Gemtuzumab Ozogamicin in Relapsed Acute Myeloid Leukemia
Medical Benefit Injectable Drugs | Kaiser Permanente Washington
Top View
Gemtuzumab Ozogamicin) for Injection, for Intravenous Hypersensitivity to MYLOTARG Or Any of Its Components (4)
Antibody–Drug Conjugates—A Tutorial Review
Standard and Novel Therapeutic Hematology Agents for the New Advanced Practice Provider
Uses of Monoclonal Antibodies for the Treatment of Non-Hodgkin
Cardiotoxicity of Novel Targeted Hematological Therapies
Acquired Resistance to Antibody-Drug Conjugates
A Xenograft Model of Macrophage Activation Syndrome Amenable to Anti-CD33 and Anti–IL-6R Treatment
The Evolution of Antibodies Into Versatile Tumor-Targeting Agents
Gemtuzumab Ozogamicin Reduces Relapse Risk in FLT3/ITD Acute Myeloid Leukemia: a Report from the Children's Oncology Group Katherine Tarlock1, Todd A
Recently Approved Therapies and Drugs in Development
Extravasation
Gemtuzumab Ozogamicin for Injection) for Intravenous Use Only Rx Only
The Role of Gemtuzumab Ozogamicin in the Treatment of Acute Myeloid Leukemia Patients
AML Gemtuzumab Ozogamicin
Oncology Medications Policy (1403)
Targeted Therapies in Hematology and Their Impact on Patient Care
Breast Cancer in Focus
Oncology Therapy for the Generalist
MP-2.139 Uses of Monoclonal Antibodies for the Treatment of Non
Mandatory Specialty Drug List
Gemtuzumab Ozogamicin in Acute Myeloid Leukemia
Prior Authorization and Investigational Services List
Prior Authorization List for Drugs
June 30, 2021 Total Approvals 269 This Report Will Be Updated January and July of Every Year
Clinical Pharmacology Strategies in Supporting Drug Development and Approval of Antibody–Drug Conjugates in Oncology
Monoclonal Antibodies As Therapeutic Agents in Oncology and Antibody Gene Therapy
Antibody–Drug Conjugates: Future Directions in Clinical And
Clinical Roundtable Monograph
Pharmacokinetics of Therapeutic Monoclonal Antibodies Used in Oncology
Monoclonal Antibodies for Non-Hodgkin Lymphoma and Acute Myeloid Leukemia in the Non-Hematopoietic Stem Cell Transplant Setting
Cytotoxic Activity of Gemtuzumab Ozogamicin (Mylotarg) in Acute Myeloid Leukemia Correlates with the Expression of Protein Kinase Syk
Discontinuation of Tyrosine Kinase Inhibitors in Patients with Chronic Myelogeneous Leukemia – You Can Do This at Home If You Read the Instructions Charles A
Therapeutics & Toxins News
Mylotarg, INN-Gemtuzumab Ozogamicin